We could replace a lifetime of daily blood thinners with just a one-time tweak to your blood cells.
March 30, 2026
Original Paper
Epigenome editing of human hematopoietic stem cells enables sustained and reversible thrombosis prevention
bioRxiv · 10.64898/2026.03.27.714536
The Takeaway
Scientists used epigenome editing to 'silence' a clotting gene in the body's stem cell factory, creating a permanent defense against strokes and heart attacks. Unlike traditional gene editing, this does not change the DNA sequence and is fully reversible if the patient ever needs to clot normally again.
From the abstract
Thrombosis remains a major cause of cardiovascular and cerebrovascular diseases, driven in large part by platelet activation and aggregation. Because platelets are continuously produced from hematopoietic stem cells (HSCs), durable reprogramming of HSC output offers a unique opportunity for a one-time antithrombotic intervention. Here, we show that DNA methylation-based epigenome editors delivered transiently as RNA result in stable, heritable gene silencing in primary human HSCs that persists t